1.Effects of CTGF gene silencing on expression of type Ⅰ collagen in a nude mouse model
Yong DU ; Peisheng JIN ; Aijun ZHANG ; Changbo TAO ; Xueyang LI ; Qiang LI ; Caiqi SHEN
Chinese Journal of Medical Aesthetics and Cosmetology 2013;(2):126-129
Objective To investigate the specific silencing of connective tissue growth factor (CTGF) in a nude mouse keloid model,using RNA interference (RNAi) technique,and to provide the basis for gene therapy of keloid.Methods The nude mouse keloid model was established,and then transfected in vivo with well-amplifiating plasmid.The mRNA expression levels of CTGF mRNA and type Ⅰ collagen mRNA were detected with reverse transcription-polymerase chain reaction (RT-PCR).The distribution and protein expression levels of CTGF and type Ⅰ collagen were determined quantitatively using immunohistochemistry.Results The expression of CTGF at mRNA and protein levels was decreased in the experiment group,and the expression of type Ⅰ collagen at mRNA and protein levels was also decreased after transfection,as compared with negative control group and blank group,with significant difference between groups (P<0.05).Moreover,the expression of type Ⅰ collagen and CTGF was positively correlated (r=0.979).Conclusions Keloid type Ⅰ collagen can be decreased through in vivo inhibiting CTGF expression.The transfection of CTGF gene in vivo may have effects on type Ⅰ collagen generation,and thus inhibit the keloid growth.
2.The nutritional management of hepatic glycogen storage diseases
Chinese Journal of Applied Clinical Pediatrics 2020;35(20):1546-1548
Hepatic glycogen storage diseases (GSDs) are a group of rare inherited disorders of glycogen metabolism.Currently, since there is no specific treatment, nutritional therapy becomes the most effective way to reduce and relieve clinical symptoms.Although all types of hepatic GSDs are mainly treated with raw cornstarch, for different subtypes of hepatic GSDs, specific treatment strategies and management are different, so as to the key issues concerned during the follow-up.Therefore, attention should be paid to the long-term nutritional management of patients with different types of hepatic GSDs.
3.Research progress of the efficacy and safety of 3-month depot Leuprorelin in the treatment of central precocious puberty
Feng YE ; Shengjuan JIN ; Caiqi DU ; Xiaoping LUO
Chinese Journal of Applied Clinical Pediatrics 2022;37(23):1828-1832
Central precocious puberty (CPP) is a common pediatric endocrine disease caused by premature activation of the hypothalamic-pituitary-gonadal axis, featured by rapid development of internal and external reproductive organs and secondary sexual characteristics in girls before age 8 and boys before age 9.The gonadotropin-releasing hormone analogue (GnRHa) is the first choice for the treatment of CPP.Currently, 3.75 mg/ month sustained -release short-acting dosage form (1M depot formulations) is the most commonly used in China.The development of long-acting dosage form will reduce injection times and clinic visits.At present, the 3-month long-acting dosage form (11.25 mg 3M depot formulations) of Leprorelin microsphere has been approved in China.However, clinical practice experience of 3-month Leuprorelin acetate depot formulations is lacking in China.Therefore, in this paper, existing clinical evidence for this dosage form was reviewed to provide evidence-based medicine support for its clinical application.
4.The application of continuous glucose monitoring in the management of hepatic glycogen storage disease
Caiqi DU ; Hong WEI ; Cai ZHANG ; Min ZHANG ; Minghui HU ; Ling HOU ; Wei WU ; Yan LIANG ; Xiaoping LUO
Chinese Journal of Pediatrics 2021;59(6):452-458
Objective:Continuous glucose monitoring (CGM) were performed in children with hepatic glycogen storage disease (GSD) to accurately understand the situation of glucose levels during their treatment, and to provide support for optimizing their nutritional management.Methods:In this retrospective research, 42 patients with hepatic GSD who under went 72 h CGM were collected from Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology from October 2019 to January 2020. According to the genetic test results, they were divided into 5 groups: type Ⅰa, type Ⅰb, type Ⅲa, type Ⅵ and type Ⅸa. After long-term follow up and regular treatment, the clinical data (induding course, age, height, weight and biochemical parameters, etc.) on the day of CGM were summarized, and 72 h CGM were performed to assess the occurrence of hypoglycemia and hyperglycemia.χ2 test, Fisher exact probability method, t test, analysis of variance or nonparametric test were used for comparison between groups. Results:Forty-two cases of hepatic GSD patients included 25 males and 17 females (20 cases of type Ⅰa, 3 cases of type Ⅰb, 10 cases of type Ⅲa, 3 cases of type Ⅵ and 6 cases of type Ⅸa).The age was 9.5 (6.7, 12.9) years, and the course of disease was 6.8 (5.1, 11.3) years. The average levels of glucose of the patients were all normal. However, the levels of standard deviation of blood glucose (SDBG) and mean amplitude of glycemic excursion (MAGE) were significantly different ( F=2.747, 3.029,both P<0.05). Among them, the SDBG of type Ⅰa and Ⅲa were significantly higher than those of type Ⅸa ((1.10±0.36), (0.98±0.30) vs. (0.62±0.26) mmol/L, t=3.010, 2.440, both P<0.05), while the MAGE of type Ⅰ was higher than that of Ⅸa and Ⅲa ((2.3±0.9) mmol/L vs. (1.2±0.6) and (1.7±0.6) mmol/L, t=2.734, 2.302, both P<0.05, respectively). Conclusions:CGMS can accurately assess the fluctuations of blood glucose and effectively detect hidden hypoglycemia and hyperglycemia in hepatic GSD patients. For different types of hepatic GSD, individualized corn starch treatment doses should be given according to the different situation of blood glucose, so as to optimize the patient′s treatment and improve their prognosis.
5.Prevalence of vitamin D deficiency in girls with idiopathic central precocious puberty.
Yue ZHAO ; Wenjun LONG ; Caiqi DU ; Huanhuan YANG ; Shimin WU ; Qin NING ; Xiaoping LUO
Frontiers of Medicine 2018;12(2):174-181
The relationship between vitamin D deficiency and idiopathic central precocious puberty (ICPP) has been recently documented. In this study, 280 girls diagnosed with ICPP and 188 normal puberty control girls of similar ages were enrolled and retrospectively studied. The ICPP group had significantly lower serum 25-hydroxyvitamin D (25[OH]D) levels than the control group. Furthermore, a nonlinear relationship was found between serum 25[OH]D and ICPP, and a cut-off point for serum 25[OH]D was found at 31.8 ng/ml for ICPP with and without adjusting the different confounding factors. Girls with serum 25[OH]D ≥ 31.8 ng/ml had a lower odds ratio (unadjusted: OR 0.36, 95% CI 0.15 to 0.83, P < 0.05; height and weight adjusted: OR 0.44, 95% CI 0.18 to 1.08, P = 0.072; BMI adjusted: OR 0.36, 95% CI 0.16 to 0.84, P < 0.05). The ICPP subjects with 25[OH]D deficiency had a higher body mass index (BMI) than the subjects from the two other subgroups. Correlation analysis showed that vitamin D level is correlated with BMI and some metabolic parameters in the ICPP group. Our study suggested that vitamin D status may be associated with ICPP risk and may have a threshold effect on ICPP.
Body Mass Index
;
Child
;
China
;
Female
;
Humans
;
Linear Models
;
Logistic Models
;
Multivariate Analysis
;
Puberty, Precocious
;
blood
;
complications
;
Retrospective Studies
;
Vitamin D
;
analogs & derivatives
;
blood
;
Vitamin D Deficiency
;
epidemiology